ATE307804T1 - Effiziente durch liganden vermittelte ullmann kupplung von anilinen und azolen - Google Patents

Effiziente durch liganden vermittelte ullmann kupplung von anilinen und azolen

Info

Publication number
ATE307804T1
ATE307804T1 AT01959231T AT01959231T ATE307804T1 AT E307804 T1 ATE307804 T1 AT E307804T1 AT 01959231 T AT01959231 T AT 01959231T AT 01959231 T AT01959231 T AT 01959231T AT E307804 T1 ATE307804 T1 AT E307804T1
Authority
AT
Austria
Prior art keywords
azoles
anilines
ullmann coupling
efficient ligand
mediated ullmann
Prior art date
Application number
AT01959231T
Other languages
English (en)
Inventor
Jia Cheng Zhou
Pasquale N Confalone
Hui-Yin Li
Lynette M Oh
Lucius T Rossano
Charles G Clark
Christopher A Teleha
Philip Ma
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE307804T1 publication Critical patent/ATE307804T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/38One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Executing Machine-Instructions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
AT01959231T 2000-07-26 2001-07-26 Effiziente durch liganden vermittelte ullmann kupplung von anilinen und azolen ATE307804T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22093200P 2000-07-26 2000-07-26
PCT/US2001/023541 WO2002008199A2 (en) 2000-07-26 2001-07-26 Efficient ligand-mediated ullmann coupling of anilines and azoles

Publications (1)

Publication Number Publication Date
ATE307804T1 true ATE307804T1 (de) 2005-11-15

Family

ID=22825611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01959231T ATE307804T1 (de) 2000-07-26 2001-07-26 Effiziente durch liganden vermittelte ullmann kupplung von anilinen und azolen

Country Status (22)

Country Link
US (1) US6541639B2 (de)
EP (1) EP1307431B1 (de)
JP (1) JP2004504384A (de)
KR (1) KR20030060872A (de)
CN (1) CN1444565A (de)
AT (1) ATE307804T1 (de)
AU (1) AU2001280813A1 (de)
BR (1) BR0112746A (de)
CA (1) CA2417426A1 (de)
DE (1) DE60114424T2 (de)
EC (1) ECSP034453A (de)
ES (1) ES2251501T3 (de)
HU (1) HUP0301699A3 (de)
IL (1) IL153547A0 (de)
IS (1) IS6695A (de)
MX (1) MXPA03000686A (de)
NO (1) NO20030393L (de)
NZ (1) NZ523271A (de)
PL (1) PL361233A1 (de)
RU (1) RU2003103706A (de)
WO (1) WO2002008199A2 (de)
ZA (1) ZA200300039B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445159C (en) * 2001-04-24 2012-09-11 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
CN101613321A (zh) 2002-03-05 2009-12-30 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
EP1509502A1 (de) * 2002-05-31 2005-03-02 Rhodia Chimie Verfahren zur herstellung einer kohlenstoff-kohlenstoff oder kohlenstoff-heteroa
AU2003257062A1 (en) 2002-08-02 2004-02-23 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
WO2004031143A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
BRPI0410436A (pt) * 2003-05-20 2006-05-30 Transtech Pharma Inc antagonistas de rage como agentes para amiloidose reversa e doenças associadas com a mesma
EP1768947A1 (de) * 2004-07-16 2007-04-04 DSMIP Assets B.V. Verfahren zur herstellung eines (hetero)arylamins
CN101796051B (zh) 2007-03-12 2013-11-06 细胞内治疗公司 与取代的杂环稠合的γ-咔啉的合成
WO2011041198A1 (en) 2009-09-30 2011-04-07 Transtech Pharma, Inc. Substituted imidazole derivatives for treatment of alzheimers disease
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
ES2893621T3 (es) 2013-12-03 2022-02-09 Intra Cellular Therapies Inc Métodos para el tratamiento de los síntomas residuales de la esquizofrenia
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
KR20170012209A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2015171951A1 (en) * 2014-05-07 2015-11-12 The Regents Of The University Of Colorado, A Body Corporate 2-(4-aryl-1h-imidazol-1-yl)aniline compounds
DK3407888T3 (da) 2016-01-26 2021-04-06 Intra Cellular Therapies Inc Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser
JP6686168B2 (ja) 2016-03-25 2020-04-22 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
CN116327770A (zh) 2017-03-24 2023-06-27 细胞内治疗公司 新组合物和方法
AU2018307480B2 (en) 2017-07-26 2023-11-23 Intra-Cellular Therapies, Inc. Organic compounds
CN111093665A (zh) 2017-07-26 2020-05-01 细胞内治疗公司 有机化合物
EP3762368B1 (de) 2018-03-08 2022-01-26 Incyte Corporation Aminopyrazindiolverbindungen als pi3k-y-hemmer
JP7483671B2 (ja) 2018-06-11 2024-05-15 イントラ-セルラー・セラピーズ・インコーポレイテッド 置換ヘテロ環縮合ガンマ-カルボリン類合成
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
KR20210052472A (ko) 2018-08-31 2021-05-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
EP3843738A4 (de) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. Neuartige verfahren
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372658A (ja) 1986-09-17 1988-04-02 Sumitomo Chem Co Ltd ニトロジフエニルアミン類の製造方法
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.

Also Published As

Publication number Publication date
WO2002008199A2 (en) 2002-01-31
ECSP034453A (es) 2003-03-31
NO20030393L (no) 2003-03-24
DE60114424T2 (de) 2006-07-27
RU2003103706A (ru) 2004-08-10
HUP0301699A3 (en) 2004-03-29
US6541639B2 (en) 2003-04-01
IS6695A (is) 2003-01-22
HUP0301699A2 (hu) 2003-12-29
EP1307431B1 (de) 2005-10-26
ES2251501T3 (es) 2006-05-01
IL153547A0 (en) 2003-07-06
WO2002008199A3 (en) 2002-06-13
ZA200300039B (en) 2004-04-02
US20020099225A1 (en) 2002-07-25
BR0112746A (pt) 2003-09-09
NO20030393D0 (no) 2003-01-24
KR20030060872A (ko) 2003-07-16
MXPA03000686A (es) 2003-06-06
DE60114424D1 (de) 2005-12-01
CN1444565A (zh) 2003-09-24
AU2001280813A1 (en) 2002-02-05
EP1307431A2 (de) 2003-05-07
PL361233A1 (en) 2004-10-04
NZ523271A (en) 2005-01-28
JP2004504384A (ja) 2004-02-12
CA2417426A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
ATE307804T1 (de) Effiziente durch liganden vermittelte ullmann kupplung von anilinen und azolen
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
PT1131318E (pt) Processo para a producao de pirazoles 5-substituidos utilizando ditietanos
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
ATE328874T1 (de) Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
AU2002350961A1 (en) Ethylene diamine derivatives and their use as orexin-receptor antagonists
ATE314371T1 (de) Spiro-indole als y5-rezeptor antagonisten
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
ATE225772T1 (de) Thrombin-inhibitoren
PL354976A1 (en) Factor ix/factor ixa antibodies and antibody derivatives
PT1671949E (pt) Piridinilaminas substituídas
IL161966A0 (en) Aryloxyphenyl and arylsulfanylphenyl
AU3110999A (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
ATE318189T1 (de) Reinigungsverfahren welches ultraschallwellen verwendet
ATE299139T1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
GB0011358D0 (en) Novel use
MY133969A (en) Indoloquinazolinones
DK1377574T3 (da) 6-phenylbenzonaphtyridiner
PT941975E (pt) Cimento para injeccao contendo inibidores de corrosao
SE0302361D0 (sv) Inhibering av upptagning av monoamin
AU2002258437A1 (en) Peptide deformylase inhibitors
AU2002322396A1 (en) 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists
CY1110139T1 (el) Γλυκοπεπτιδικα αντιβιοτικα
DE60232650D1 (de) Peptiddeformylaseinhibitoren
AU2002255635A1 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties